newdrugapprovals.org
Janssen signs licensing agreement with PATH for development of HIV-1 drug
rilpivirine. Janssen R&D Ireland has signed a licensing agreement with PATH for the early development of a long-acting depot formulation of the human immunodeficiency virus type 1 (HIV-1) drug …